Samsara BioCapital, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001744967
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2025 · 37 positions · Total reported value $560.81M · Top-10 concentration 86.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 37.0% · 3 new · 7 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q1 2025 13F filing, Samsara BioCapital, LLC disclosed 37 equity positions with a combined reported value of $560.81M. The filing implies a focused portfolio: its ten largest positions account for 86.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2025 were SRRK ($180.45M), KLRS ($91.93M), MLYS ($90.12M). By sector, the heaviest allocations are Health Care 92.2%, Other 7.8%. Versus the prior quarter, allocation shifted toward Health Care (+8.0pp) and away from Other (-8.0pp).
Versus the prior quarter, Samsara BioCapital, LLC opened 3 new positions, trimmed 7 and fully exited 0, a turnover rate of 37.0% of positions. The portfolio's overlap with the prior quarter was 78% of names.
The largest new positions opened in Q1 2025 were KLRS ($91.93M), SRZN ($2.81M).
Of the 8 positions fully exited versus the prior quarter, the largest were JSPR ($12.50M), ACRS ($5.91M), CLYM ($4.70M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2025)
- KLRS KALARIS THERAPEUTICS INC · $91.93M
- SRZN SURROZEN INC · $2.81M
Fully Exited (vs previous quarter)
- JSPR JASPER THERAPEUTICS INC · prev qtr: $12.50M
- ACRS ACLARIS THERAPEUTICS INC · prev qtr: $5.91M
- CLYM CLIMB BIO INC · prev qtr: $4.70M
- VRNA VERONA PHARMA PLC · prev qtr: $4.53M
- DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $1.87M
- IMTX Immatics NV · prev qtr: $1.41M
- JANX JANUX THERAPEUTICS INC · prev qtr: $603.02K
- ALVR ALLOVIR INC · prev qtr: $34.58K
Insider Transactions (Form 4)
Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 27 positions worth $1.05B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- SEC registration: 801-113741 (status: Approved), registered 2018-07-27
- Regulatory AUM (Form ADV): $2.17B as of 2026-10-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds
Portfolio Structure
- 27 positions · $1.05B reported value (Q3 2026)
- Top 10 holdings = 87.9% of reported value
- Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.7%
- Average position size: $38.95M
Sector Tilt
- Health Care 91.8%
- Industrials 8.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 3 new, 3 added, 7 reduced
- 14 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.61M | $180.45M | 32.18% | Hold | |
| 2 |
|
11.45M | $91.93M | 16.39% | New | |
| 3 |
|
5.67M | $90.12M | 16.07% | Add | |
| 4 |
|
1.72M | $20.11M | 3.58% | Hold | |
| 5 |
|
3.27M | $20.06M | 3.58% | Hold | |
| 6 |
|
679.49K | $19.02M | 3.39% | Hold | |
| 7 |
|
3.15M | $18.23M | 3.25% | Add | |
| 8 |
|
4.42M | $17.97M | 3.21% | Hold | |
| 9 |
|
526.39K | $13.53M | 2.41% | Reduce | |
| 10 |
|
2.07M | $12.65M | 2.26% | Reduce | |
| 11 |
|
135.28K | $8.87M | 1.58% | Reduce | |
| 12 |
|
666.67K | $7.94M | 1.42% | Reduce | |
| 13 |
|
967.53K | $7.58M | 1.35% | Hold | |
| 14 |
|
138.12K | $7.32M | 1.30% | Reduce | |
| 15 |
|
3.77M | $6.93M | 1.24% | Hold | |
| 16 |
|
6.13M | $6.74M | 1.20% | Hold | |
| 17 |
|
2.52M | $6.23M | 1.11% | Hold | |
| 18 |
|
588.82K | $4.11M | 0.73% | Hold | |
| 19 |
|
206.78K | $3.58M | 0.64% | Hold | |
| 20 |
|
824.15K | $3.54M | 0.63% | Hold | |
| 21 |
|
241.40K | $2.81M | 0.50% | New | |
| 22 |
|
425.00K | $2.66M | 0.47% | Reduce | |
| 23 |
|
2.20M | $1.43M | 0.26% | Hold | |
| 24 |
|
1.56M | $1.42M | 0.25% | Hold | |
| 25 |
|
291.67K | $875.00K | 0.16% | Hold | |
| 26 |
|
630.00K | $863.10K | 0.15% | Hold | |
| 27 |
|
405.23K | $806.40K | 0.14% | Hold | |
| 28 |
|
2.44M | $745.16K | 0.13% | Hold | |
| 29 |
|
399.64K | $579.47K | 0.10% | Hold | |
| 30 |
|
202.35K | $558.48K | 0.10% | Hold | |
| 31 |
|
1.05M | $419.66K | 0.07% | Hold | |
| 32 |
|
185.94K | $390.48K | 0.07% | Reduce | |
| 33 |
|
1.39M | $175.57K | 0.03% | Reduce | |
| 34 |
|
78.13K | $64.46K | 0.01% | Hold | |
| 35 |
|
133.33K | $42.67K | 0.01% | Hold | |
| 36 |
|
172.09K | $39.17K | 0.01% | Hold | |
| 37 |
|
100.00K | $3.00K | 0.00% | Hold | |
FAQ
What did Samsara BioCapital, LLC buy in 2025-Q1?
In its 2025-Q1 13F filing, Samsara BioCapital, LLC reported 37 equity positions worth $560.81M in aggregate; its largest disclosed positions were SRRK ($180.45M), KLRS ($91.93M), MLYS ($90.12M).
How large is Samsara BioCapital, LLC's portfolio?
Samsara BioCapital, LLC reported $560.81M of long equity holdings across 37 positions as of 2025-Q1. Top-10 holdings account for 86.3% of reported value.
What is Samsara BioCapital, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.